2016 New treatment, B-cells, T-cells, General Immune System Function
Testing a new monoclonal antibody to stop an enzyme that drives autoimmune disease
The study and what it means to patients
"We are excited to test the effectiveness of a potential new treatment - a newly developed monoclonal antibody -- to inactivate an enzyme we found is responsible for driving the production of autoantibodies that attack the body's own tissues."
A common characteristic of lupus is the presence of antibodies directed against the body's own tissues, known as autoantibodies. Understanding the factors that activate and perpetuate the production of these autoantibodies is important in the design of therapeutic strategies for the prevention and treatment of this debilitating autoimmune disease.
Our novel research will investigate a potential treatment, a new monoclonal antibody that targets the immune-regulating enzyme IDO2, and that, we believe, will interfere with the production of autoantibodies involved in lupus. In the future, this promising drug could lead to new treatments for lupus and its related symptoms.
Systemic Lupus Erythematosus (SLE) is a heterogeneous disease characterized by autoantibody production. Several new therapies have been designed to inhibit autoantibodies by interfering with B cell differentiation or survival, however these treatments are not always effective and there is a continuing need for new therapeutic strategies to address the underling causes of SLE. The studies in this proposal will investigate a new therapeutic strategy to block the autoimmune response by inhibition of the immunomodulatory enzyme indoleamine-2,3-dioxygenase 2 (IDO2). Using a combination of genetic and pharmacological studies in a preclinical model of arthritis, we demonstrated a critical role for IDO2 in driving B cell-mediated autoimmunity. Mechanistic investigations revealed that IDO2 was needed to activate T helper cells, generate pathogenic autoantibodies, and drive disease development. This led us to hypothesize that targeting IDO2 would also be an effective strategy to block the autoimmune response driving SLE. In this proposal, we will use a well-characterized preclinical model of SLE to examine the effectiveness of a newly developed IDO2 monoclonal antibody therapy in reducing the production of autoantibodies, inflammatory cytokines, and glomerulonephritis characteristic of SLE. If successful, this work could lead to a new strategy to prevent and treat autoantibody- mediated disease in SLE patients.